Volume 27, Number 11—November 2021
Dispatch
COVID-19 Vaccination Coverage, Intent, Knowledge, Attitudes, and Beliefs among Essential Workers, United States
Kimberly H. Nguyen
, David Yankey, Kelsey C. Coy, Kathryn A. Brookmeyer, Neetu Abad, Rebecca Guerin, Girija Syamlal, Peng-jun Lu, Brittney N. Baack, Hilda Razzaghi, Andrea Okun, and James A. Singleton
, David Yankey, Kelsey C. Coy, Kathryn A. Brookmeyer, Neetu Abad, Rebecca Guerin, Girija Syamlal, Peng-jun Lu, Brittney N. Baack, Hilda Razzaghi, Andrea Okun, and James A. Singleton
Table 2
Motivators for getting a COVID-19 vaccine, by essential worker group and vaccination intent, United States, March–June 2021*
| Reason | All groups, n = 5,308 |
Healthcare personnel,
n = 1,308 |
Frontline workers,
n = 2,300 |
Other workers, n = 1,700 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total† | R, n = 714 | RL, n = 1,059 | Total | R, n = 121 | RL, n = 197 | Total | R, n = 316 | RL, n = 437 | Total | R, n = 277 | RL, n = 425 | ||||
| Prevent COVID-19 spread to family and friends |
51.4 (49.6–53.2) |
26.0 (22.0–30.3) |
4.7 (3.1–6.9) |
58.0 (54.4–61.4) |
30.5 (20.3–42.3) |
7.7 (2.5–17.2)† |
50.5 (47.7–53.3) |
30.7 (24.4–37.5) |
4.1 (2.2–6.8) |
47.6 (44.7–50.5) |
19.1 (13.7–25.4) |
3.7 (2.0–6.3) |
|||
| More information on vaccine effectiveness |
44.4 (42.7–46.2) |
31.1 (26.7–35.7) |
14.1 (11.6–16.9) |
46.0 (42.6–49.4) |
26.4 (17.6–36.8) |
13.7 (8.5–20.5) |
44.9 (42.3–47.5) |
29.1 (23.5–35.2) |
17.1 (13.1–21.7) |
42.6 (39.7–45.6) |
35.0 (27.7–42.9) |
11.0 (7.4–15.6) |
|||
| Reduce COVID-19 spread in community |
41.9 (40.2–43.6) |
19.4 (15.9–23.2) |
2.9 (1.7–4.7) |
45.8 (42.3–49.4) |
14.5 (8.3–23.0) |
3.0 (1.1–6.5)† |
42.5 (39.8–45.2) |
20.9 (16.0–26.6) |
3.2 (1.0–7.3)† |
37.9 (35.0–40.9) |
19.4 (13.5–26.4) |
2.6 (1.1–5.2) |
|||
| Ability to resume social activities |
36.7 (35.0–38.3) |
15.5 (12.3–19.2) |
2.2 (1.3–3.3) |
38.5 (35.1–42.0) |
9.0 (4.5–15.7) |
1.2 (0.2–3.8) |
37.7 (35.3–40.2) |
14.3 (9.9–19.6) |
3.6 (1.9–6.1) |
33.8 (31.1–36.5) |
19.3 (13.4–26.3) |
1.2 (0.4–2.8) |
|||
| More severe COVID-19 cases |
33.4 (31.8–35.0) |
13.7 (10.8–17.0) |
4.8 (3.4–6.6) |
36.2 (32.9–39.5) |
14.4 (7.8–23.6) |
2.2 (0.7–5.4) |
33.6 (31.2–36.1) |
13.1 (9.1–18.1) |
6.2 (3.5–10.0) |
30.9 (28.3–33.6) |
14.0 (9.3–19.9) |
4.7 (2.7–7.5) |
|||
| Ability to travel |
31.3 (29.8–32.8) |
16.9 (13.8–20.5) |
6.9 (5.1–9.1) |
32.5 (29.2–35.9) |
15.0 (8.1–24.5) |
7.4 (3.2–14.2)† |
32.4 (30.1–34.7) |
16.4 (12.1–21.6) |
6.4 (4.1–9.4) |
28.8 (26.2–31.4) |
18.3 (12.7–24.9) |
7.1 (4.3–10.8) |
|||
| Someone I know became seriously ill or died from COVID-19 |
22.1 (20.8–23.5) |
9.4 (6.8–12.6) |
6.4 (4.6–8.5) |
24.1 (21.4–27.0) |
11.7 (5.6–21.0)† |
2.7 (0.8–6.6)† |
21.7 (19.7–23.9) |
11.5 (6.9–17.8) |
8.0 (5.2–11.6) |
21.0 (18.7–23.4) |
6.1 (3.6–9.6) |
6.6 (3.9–10.4) |
|||
| Recommend by a healthcare provider |
17.2 (16.0–18.5) |
14.1 (10.9–17.9) |
3.6 (2.2–5.5) |
19.9 (17.4–22.6) |
13.5 (6.3–24.2)† |
3.9 (0.8–11.0)† |
16.8 (14.9–18.7) |
15.5 (10.8–21.2) |
4.2 (2.2–7.4) |
15.7 (13.7–17.9) |
12.9 (7.7–19.8) |
2.8 (1.2–5.5) |
|||
| Workplace or school requirement |
14.9 (13.8–16.1) |
29.1 (25.0–33.5) |
14.2 (11.8–17.0) |
19.9 (17.2–22.9) |
39.5 (28.6–51.2) |
10.8 (6.5–16.7) |
13.7 (12.0–15.4) |
27.2 (21.6–33.5) |
17.1 (13.0–21.9) |
12.8 (10.8–15.0) |
27.4 (20.9–34.7) |
13.0 (9.4–17.4) |
|||
| Vaccine safety information available |
14.8 (13.4–16.3) |
39.8 (35.4–44.5) |
20.8 (17.9–24.1) |
11.7 (9.3–14.6) |
46.6 (35.6–57.9) |
21.2 (14.7–28.9) |
14.2 (12.2–16.4) |
36.8 (30.5–43.3) |
21.7 (17.1–26.8) |
18.0 (15.2–21.1) |
40.7 (33.3–48.6) |
19.7 (15.1–25.1) |
|||
| Enables children back to school |
14.8 (13.6–16.0) |
8.1 (5.9–10.9) |
1.5 (0.7–2.8) |
16.5 (13.9–19.3) |
12.6 (5.6–23.3)† |
2.0 (0.6–5.1) |
16.0 (14.2–17.8) |
8.5 (5.4–12.4) |
2.2 (0.6–5.2) |
11.8 (10.0–13.8) |
6.1 (3.3–10.1) |
0.4 (0.0–1.6) |
|||
| Enables me to get back to work or school |
12.4 (11.2–13.7) |
4.8 (3.2–7.0) |
1.4 (0.7–2.7) |
14.3 (11.7–17.3) |
2.2 (0.4–6.7)† |
1.7 (0.4–4.6) |
14.9 (13.0–16.8) |
6.4 (3.7–10.3) |
2.0 (0.5–5.1) |
7.5 (6.1–9.2) |
4.1 (1.9–7.5)† |
0.7 (0.1–2.1) |
|||
| Recommended by a family member or friend |
11.9 (10.8–13.0) |
5.4 (3.7–7.7) |
1.3 (0.6–2.4) |
11.2 (9.0–13.7) |
7.6 (2.3–17.8)† |
2.2 (0.6–5.3) |
13.0 (11.4–14.8) |
5.9 (3.4–9.4) |
1.7 (0.5–4.4) |
10.8 (9.1–12.6) |
4.2 (2.1–7.2) |
0.3 (0.0–1.3) |
|||
| See community members getting vaccinated |
10.3 (9.1–11.5) |
5.2 (3.4–7.5) |
2.6 (1.3–4.6) |
10.5 (8.2–13.2) |
10.2 (3.7–21.3)† |
2.1 (0.6–5.2) |
11.7 (9.8–13.8) |
5.3 (3.0–8.6) |
4.5 (1.7–9.4)† |
8.2 (6.7–9.9) |
3.2 (1.4–6.0) |
0.7 (0.1–2.2) |
|||
| Large increase in COVID-19 cases in my area |
3.1 (2.5–3.9) |
10.1 (7.7–13.0) |
3.2 (2.0–4.9) |
2.3 (1.2–4.1) |
13.5 (6.4–24.1)† |
2.1 (0.5–5.3) |
3.2 (2.2–4.4) |
7.8 (5.1–11.4) |
5.1 (2.6–8.8) |
3.7 (2.5–5.4) |
11.4 (7.2–17.1) |
1.8 (0.7–3.7) |
|||
| None of the above | 19.9 (18.3–21.5) | 14.1 (11.1–17.6) | 55.9 (52.1–59.6) | 15.6 (12.3–19.4) | 10.7 (5.8–17.7) | 54.1 (44.3–63.6) | 17.7 (15.4–20.1) | 11.9 (8.1–16.7) | 52.7 (46.6–58.7) | 26.2 (23.3–29.2) | 17.8 (12.1–24.9) | 60.5 (54.5–66.3) | |||
*Values are reported as % respondents (95% CI). n values indicate unweighted sample size/denominator. Bold text indicates statistical significance (p<0.05) between reachable and reluctant groups; reluctant group is the referent. R respondents were defined as adults who probably would or were unsure about getting a COVID-19 vaccine. RL respondents were defined as adults who probably or definitely would not get a COVID-19 vaccine. COVID-19, coronavirus disease; R, reachable; RL, reluctant.
†Estimates do not meet the National Center for Health Statistics standards of reliability (https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf).
Page created: August 27, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.